New drug cocktail targets Hard-to-Treat amyloidosis
NCT ID NCT04847453
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-stage trial tests a combination of three drugs—venetoclax, ixazomib, and dexamethasone—in 24 patients with light chain amyloidosis that has returned or not responded to prior treatment. The study focuses on finding the safest dose and checking side effects. All participants must have a specific genetic change called t(11;14).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax, ixazomib citrate, and dexamethasone
- What this could lead to
- If successful, this could provide a new treatment option for patients with relapsed or refractory light chain amyloidosis who have a specific genetic change.
- What could go wrong
- This is an early phase 1 trial with only 24 participants, so the safety and effectiveness are not yet proven. Side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- New scan spots hidden organ damage before symptoms start
- Could a simple scan unlock better heart treatment?